CYCN
Cyclerion Therapeutics, Inc.
Biotechnology
Market Cap$14M
5Y Perf.-95.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CYCN vs MNKD
Revenue, margins, valuation, and 5-year total return — side by side.
MNKD
MannKind Corporation
Biotechnology
Market Cap$1.10B
5Y Perf.+135.8%
CYCN vs MNKD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CYCN | MNKD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $14M | $1.10B |
| Revenue (TTM) | $2M | $361M |
| Net Income (TTM) | $-4M | $-24M |
| Gross Margin | 100.0% | 79.3% |
| Operating Margin | -239.8% | 4.1% |
| Forward P/E | — | 218.4x |
| Total Debt | $0.00 | $473M |
| Cash & Equiv. | $3M | $75M |
CYCN vs MNKD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CYCN
MNKD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cyclerion Therapeut… (CYCN) | 100 | 4.1 | -95.9% |
| MannKind Corporation (MNKD) | 100 | 235.8 | +135.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CYCN vs MNKD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNKD leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Cyclerion Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
CYCN
Cyclerion Therapeutics, Inc.
The Growth Play
CYCN is the clearest fit if your priority is growth exposure.
- Rev growth 3.7%, EPS growth 9.9%, 3Y rev CAGR 91.1%
- +7.6% vs MNKD's -25.5%
Best for: growth exposure
MNKD
MannKind Corporation
The Income Pick
MNKD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.90
- -46.5% 10Y total return vs CYCN's -98.7%
- Lower volatility, beta 0.90, current ratio 1.70x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MNKD | 22.2% revenue growth vs CYCN's 3.7% |
| Quality / Margins | MNKD | -6.6% margin vs CYCN's -170.1% |
| Stability / Safety | MNKD | Beta 0.90 vs CYCN's 0.94 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CYCN | +7.6% vs MNKD's -25.5% |
| Efficiency (ROA) | MNKD | -3.9% ROA vs CYCN's -35.6%, ROIC 21.6% vs -65.1% |
CYCN vs MNKD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
CYCN vs MNKD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNKDLAGGINGCYCN
CYCNCyclerion Therapeutic…
0leads
MNKDMannKind Corporation
4leads
6 Total Categories
CATEGORYLEADERvs CYCNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MNKD4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNKD4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
MNKD4/6
Risk & VolatilityBeta, volatility, and downside exposure
MNKD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MNKD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MNKD is the larger business by revenue, generating $361M annually — 174.0x CYCN's $2M. MNKD is the more profitable business, keeping -6.6% of every revenue dollar as net income compared to CYCN's -170.1%. On growth, MNKD holds the edge at +15.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CYCNCyclerion Therape… | MNKDMannKind Corporat… |
|---|---|---|
| RevenueTrailing 12 months | $2M | $361M |
| EBITDAEarnings before interest/tax | -$5M | $25M |
| Net IncomeAfter-tax profit | -$4M | -$24M |
| Free Cash FlowCash after capex | -$3M | $13M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +79.3% |
| Operating MarginEBIT ÷ Revenue | -2.4% | +4.1% |
| Net MarginNet income ÷ Revenue | -170.1% | -6.6% |
| FCF MarginFCF ÷ Revenue | -159.8% | +3.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -43.2% | +15.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | -2.2% |
MNKD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — CYCN and MNKD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CYCNCyclerion Therape… | MNKDMannKind Corporat… |
|---|---|---|
| Market CapShares × price | $14M | $1.1B |
| Enterprise ValueMkt cap + debt − cash | $11M | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -2.97x | 178.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 218.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 29.32x |
| Price / SalesMarket cap ÷ Revenue | 6.76x | 3.15x |
| Price / BookPrice ÷ Book value/share | 1.15x | — |
| Price / FCFMarket cap ÷ FCF | — | 80.31x |
Evenly matched — CYCN and MNKD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MNKD leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), MNKD scores 4/9 vs CYCN's 1/9, reflecting mixed financial health.
| Metric | CYCNCyclerion Therape… | MNKDMannKind Corporat… |
|---|---|---|
| ROE (TTM)Return on equity | -39.2% | — |
| ROA (TTM)Return on assets | -35.6% | -3.9% |
| ROICReturn on invested capital | -65.1% | +21.6% |
| ROCEReturn on capital employed | -55.5% | +8.3% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$3M | $399M |
| Cash & Equiv.Liquid assets | $3M | $75M |
| Total DebtShort + long-term debt | $0 | $473M |
| Interest CoverageEBIT ÷ Interest expense | — | 0.75x |
MNKD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
MNKD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNKD five years ago would be worth $8,725 today (with dividends reinvested), compared to $651 for CYCN. Over the past 12 months, CYCN leads with a +7.6% total return vs MNKD's -25.5%. The 3-year compound annual growth rate (CAGR) favors MNKD at -2.8% vs CYCN's -18.2% — a key indicator of consistent wealth creation.
| Metric | CYCNCyclerion Therape… | MNKDMannKind Corporat… |
|---|---|---|
| YTD ReturnYear-to-date | +141.8% | -36.4% |
| 1-Year ReturnPast 12 months | +7.6% | -25.5% |
| 3-Year ReturnCumulative with dividends | -45.3% | -8.2% |
| 5-Year ReturnCumulative with dividends | -93.5% | -12.7% |
| 10-Year ReturnCumulative with dividends | -98.7% | -46.5% |
| CAGR (3Y)Annualised 3-year return | -18.2% | -2.8% |
MNKD leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
MNKD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MNKD is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than CYCN's 0.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNKD currently trades 54.7% from its 52-week high vs CYCN's 38.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CYCNCyclerion Therape… | MNKDMannKind Corporat… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.94x | 0.90x |
| 52-Week HighHighest price in past year | $8.48 | $6.51 |
| 52-Week LowLowest price in past year | $1.03 | $2.23 |
| % of 52W HighCurrent price vs 52-week peak | +38.2% | +54.7% |
| RSI (14)Momentum oscillator 0–100 | 54.4 | 53.6 |
| Avg Volume (50D)Average daily shares traded | 5.5M | 6.8M |
MNKD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | CYCNCyclerion Therape… | MNKDMannKind Corporat… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $7.00 |
| # AnalystsCovering analysts | — | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.9% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNKD leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallMannKind Corporation (MNKD)Leads 4 of 6 categories
Loading custom metrics...
CYCN vs MNKD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CYCN or MNKD a better buy right now?
For growth investors, MannKind Corporation (MNKD) is the stronger pick with 22.
2% revenue growth year-over-year, versus 3. 7% for Cyclerion Therapeutics, Inc. (CYCN). MannKind Corporation (MNKD) offers the better valuation at 178. 0x trailing P/E (218. 4x forward), making it the more compelling value choice. Analysts rate MannKind Corporation (MNKD) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CYCN or MNKD?
Over the past 5 years, MannKind Corporation (MNKD) delivered a total return of -12.
7%, compared to -93. 5% for Cyclerion Therapeutics, Inc. (CYCN). Over 10 years, the gap is even starker: MNKD returned -46. 5% versus CYCN's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CYCN or MNKD?
By beta (market sensitivity over 5 years), MannKind Corporation (MNKD) is the lower-risk stock at 0.
90β versus Cyclerion Therapeutics, Inc. 's 0. 94β — meaning CYCN is approximately 5% more volatile than MNKD relative to the S&P 500.
04Which is growing faster — CYCN or MNKD?
By revenue growth (latest reported year), MannKind Corporation (MNKD) is pulling ahead at 22.
2% versus 3. 7% for Cyclerion Therapeutics, Inc. (CYCN). On earnings-per-share growth, the picture is similar: Cyclerion Therapeutics, Inc. grew EPS 9. 9% year-over-year, compared to -79. 4% for MannKind Corporation. Over a 3-year CAGR, CYCN leads at 91. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CYCN or MNKD?
MannKind Corporation (MNKD) is the more profitable company, earning 1.
7% net margin versus -170. 1% for Cyclerion Therapeutics, Inc. — meaning it keeps 1. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNKD leads at 11. 1% versus -239. 8% for CYCN. At the gross margin level — before operating expenses — CYCN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CYCN or MNKD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CYCN or MNKD better for a retirement portfolio?
For long-horizon retirement investors, MannKind Corporation (MNKD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
90)). Both have compounded well over 10 years (MNKD: -46. 5%, CYCN: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CYCN and MNKD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CYCN is a small-cap quality compounder stock; MNKD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CYCN: -43.2% · MNKD: 15.1%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.